1) Strategy & Leadership
- CEO Bryan Hanson emphasized the team's strong execution and momentum, leading to results that exceeded expectations.
- The company is nearing completion of its separation from 3M, which is expected to improve operational efficiency and free cash flow.
- Solventum is advancing the separation of its Health Information Systems (HIS) business to unlock shareholder value and refocus on MedTech.
- The company plans to host its third Annual Investor Day in Q1 2027 to outline its long-range plan post-HIS separation.

2) Financial & Segment Results
- Q2 2026 sales reached $2.2 billion, a 9.5% increase organically YoY, with a reported growth of 2.2%.
- MedSurg segment sales were $1.4 billion, up 8.9% organically, driven by advanced orders and strong performance in infection prevention.
- Dental Solutions grew 15.2% organically, while HIS reported 5.4% growth, benefiting from revenue cycle management solutions.
- Gross margins improved to 60.1%, aided by a one-time tariff refund of $100 million, while operating income was $627 million, reflecting an operating margin of 28.4%.

3) Problems / Headwinds
- The company faced challenges related to its ERP cutover, which involved advanced orders of approximately $125 million that are expected to reverse in Q3 2026.
- The impact of SKU rationalization and the timing of separations created temporary headwinds, affecting normalized organic growth rates.
- Litigation costs of $157 million were recorded, which will impact GAAP earnings but are excluded from non-GAAP measures.

4) Operational or Product Plans
- Solventum is focused on its five growth drivers, which include IV site management and advanced wound care, with nearly 20 new product launches expected by Q1 2028.
- The integration of the Acera acquisition is progressing well, with year-over-year revenue growth above 40%.
- The company is committed to maintaining its innovation pipeline, particularly in MedSurg and Dental, to drive future growth.

5) Guidance & Outlook / Investor Angle
- The company raised its organic sales growth guidance for 2026 to 2.5% to 3%, with expectations of improved performance in 2027.
- Earnings per share guidance was increased to $7.10 to $7.20, reflecting confidence in ongoing operational improvements and tariff refunds.
- The HIS separation is expected to provide clarity on future financial impacts, with ongoing updates planned as the process unfolds.

Bottom line: Solventum's Q2 results demonstrate strong execution and a clear path toward operational efficiency and growth, particularly with the upcoming HIS separation. The company is well-positioned to enhance shareholder value through focused innovation and disciplined capital allocation.